Sequestration of Clostridium Difficile Toxin

Since disease symptoms are attributed to the toxins released by C. difficile, and re-colonization of C. difficile is attributed to the inhibition of normal microbial flora growth by antibiotic treatment, selective sequestration and neutrahzation of these toxins appears to be an attractive and safe antibiotic- 

High molecular weight sodium salt of poly(styrene sulfonic acid) derivative was selected as the clinical candidate for treating C. difficile infection. This compound, under the generic name of Tolevamer, has been successful in both phase I and phase II human clinical trials. 

---